Shares of telehealth company Hims & Hers Health (NYSE: HIMS) rose 3.8% in afternoon trading today, ultimately closing at $49.34, up 3.3% from the previous trading day’s closing price. This increase was primarily driven by the company’s announcement of its official entry into the highly anticipated testosterone replacement therapy market. The company has launched a new men’s health business segment focused on providing personalized treatment plans for patients with low testosterone. According to statistics, this condition affects approximately 20 million men across the United States. The new service will immediately offer treatment options including enclomiphene compounds and, through a partnership with Marius Pharmaceuticals, will exclusively sell the FDA-approved oral testosterone medication KYZATREX® starting in 2026. This strategic move is seen as a significant step for the company to expand from its core sexual health business into the rapidly growing hormone health sector.
From a market reaction perspective, Hims & Hers Health’s stock has historically been highly volatile, with 96 instances of single-day gains exceeding 5% over the past year. Against this backdrop, today’s increase reflects positive market recognition of the news but does not significantly alter the overall assessment of the company’s fundamentals. Six days ago, the stock rose 4.9% due to strong revenue expectations and supportive actions from analysts. Earlier, the company confirmed its fiscal year 2025 revenue guidance of $2.3 to $2.4 billion, with third-quarter revenue expected to reach $570 to $590 million, driving a single-day stock gain of over 8%. Deutsche Bank subsequently raised its price target to $48 but maintained a “hold” rating. Although Bank of America Securities reiterated its “underperform” rating, it expressed “growing optimism” about the prospects of the company’s GLP-1 product line, indirectly supporting the recent stock trend.
Although Hims & Hers Health’s stock has accumulated a 95.8% gain since the beginning of the year, its current price of $49.34 is still 28.2% lower than its 52-week high of $68.74, reached in February 2025. Looking back over a five-year period, if an investor had purchased $1,000 worth of the company’s stock five years ago, its value would now be $4,495, reflecting significant long-term market capitalization growth.
